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Abstract
Background: Systematic differentiation of amyloid (Ab) species could be important for diagnosis of Alzheimer’s disease
(AD). In spite of significant progress, controversies remain regarding which species are the primary contributors to the AD
pathology, and which species could be used as the best biomarkers for its diagnosis. These controversies are partially
caused by the lack of reliable methods to differentiate the complicated subtypes of Ab species. Particularly, differentiation
of Ab monomers from toxic higher molecular weight species (HrMW) would be beneficial for drug screening, diagnosis, and
molecular mechanism studies. However, fast and cheap methods for these specific aims are still lacking.
Principal Findings: We demonstrated the feasibility of a non-conjugated FRET (Fo ¨rster resonance energy transfer)
technique that utilized amyloid beta (Ab) species as intrinsic platforms for the FRET pair assembly. Mixing two structurally
similar curcumin derivatives that served as the small molecule FRET pair with Ab40 aggregates resulted in a FRET signal,
while no signal was detected when using Ab40 monomer solution. Lastly, this FRET technique enabled us to quantify the
concentrations of Ab monomers and high molecular weight species in solution.
Significance: We believe that this FRET technique could potentially be used as a tool for screening for inhibitors of Ab
aggregation. We also suggest that this concept could be generalized to other misfolded proteins/peptides implicated in
various pathologies including amyloid in diabetes, prion in bovine spongiform encephalopathy, tau protein in AD, and a-
synuclein in Parkinson disease.
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Introduction
The amyloid b (Ab) species of Alzheimer’s disease (AD) have
been considered to be an important biomarker family. In the
course of AD development, Ab monomers gradually polymerize/
aggregate/cross-link into higher molecular weight species (HrMW)
that include small oligomers such as dimers, tetramers, and large
oligomers, profibrils, fibrils/aggregates and plaques. (Further in
this manuscript we want to differentiate between HrMW that
include all species higher than monomers and high molecular
weight speciaes (HMW) that include only large oligomers,
profibrils, fibrils/aggregates and plaques). Controversies remain
regarding which Ab species are the primary contributors to the
AD pathology [1,2] and which species could be used as the best
biomarkers for its diagnosis. However, numerous studies suggest
that all HrMW species are neurotoxic [3,4,5,6]. Identifying
potential therapeutics preventing monomeric Ab species from
transforming into higher molecular weight species would be
extremely beneficial for AD patients. Nonetheless, drug screening
for inhibitors of Ab aggregating is largely dependent on Thioflavin
assays [7,8,10]. It is well known that Thioflavin T is only effective
in monitoring the formation of HMW species that include large
oligomers, profibrils, fibrils/aggregates and plaques [7,9,10,11]
but not suitable for small oligomers that are also toxic [7,12].
Therefore, a cheap, efficient and quantitative method capable of
monitoring the aggregation from monomers to any HrMW species
is highly desirable [13].
FRET (Foster Resonance Energy Transfer) is a distance-
dependent energy transfer between two chromophores [14]. In
practice, proximity of less than 10 nm between donor and
acceptor and a substantial overlap of donor emission and acceptor
excitation spectra are essential for an efficient FRET pair [15].
The intrinsic structure of Ab aggregates/plaques represents a large
number of compacted ladders of b sheets containing Ab40/42
peptide [16,17]. Numerous small molecules could be retained in
the aggregates/plaques/oligomers, provided that they are capable
of intercalating into the b sheets. For example, the insertion of the
molecule curcumin into these b sheets has been reported [18]. We
reasoned that two non-conjugated FRET partner molecules with
the affinity for b sheets would, upon mixing with the Ab species
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19362(aggregates, fibrils and plaques), have a high probability of
randomly incorporating themselves into the Ab species with-
in10 nm proximity to generate a viable FRET signal (Fig. 1).
In this report, we first demonstrated that Ab aggregates could be
used for assisting the assembly of a FRET pair consisting of two
non-conjugated curcumin analogues, and then we extended this
concept to Ab dimers. Lastly, we demonstrated the feasibility of
differentiation of monomers from HrMW species. We believe that
the described method bears a potential in AD research for drug
screening and possible disease staging.
Results
First, we tested our non-conjugated small molecule FRET
concept by using Ab40 aggregates as the assembling platform, and
CRANAD-2 and CRANAD-5 as the small molecule FRET pair.
Ab40 aggregates were prepared as described (Material and
Methods) and the morphological structure was confirmed by
TEM (Fig. S1). We have previously shown that CRANAD-2 and
CRANAD-5, analogues of curcumin, were specific fluorescence
imaging probes for Ab species ([19] and data not shown).
Structurally, CRANAD-2 and CRANAD-5 have a similar
backbone, indicating that the two molecules may have an
analogous mechanism of interaction with Ab aggregates (Fig. 1).
Moreover, CRANAD-59s emission and CRANAD-29s excitation
have a reasonable spectral overlap (Fig. S2 lower panel), which
spans from 550 nm to 700 nm. Based on these facts, we reasoned
that CRANAD-5/CRANAD-2 could be a potential FRET pair
for Ab aggregates. Furthermore, the apparent binding affinity of
CRANAD-5 (Kd=10 nM) was very close to that of CRANAD-2
(Kd=38 nM), indicating that both probes would integrate within
Ab species with similar probabilities. Collectively, these facts
formed the basis for further testing of CRANAD-5/CRANAD-2
as a possible in vitro FRET pair.
To this end, we examined four solutions: (a) CRANAD-5 and
CRANAD-2 with Ab40 aggregates; (b) CRANAD-5 with Ab40
aggregates; (c) CRANAD-2 with Ab40 aggregates; and (d)
CRANAD-5 and CRANAD-2 without Ab40 aggregates. In our
search for the best parameters resulting in the highest FRET peak
resolution we measured the spectra of the four solutions (a–d) with
excitation at 400 nm, 420 nm, 480 nm, 500 nm, 540 nm, and
580 nm. At 420 nm excitation we observed unambiguous FRET
phenomenon with the best resolution for the peak at 700 nm (the
acceptor’s emission peak) (Fig. 2A). At this excitation, the intensity
of (a) was 30% lower than that of (b) at 610 nm (the peak emission
of the donor CRANAD-5) but it was 17-fold higher than that of (c)
at 700 nm, the peak emission of the acceptor CRANAD-2, which
could not be excited without its FRET partner CRANAD-5 at
420 nm excitation. There was no apparent FRET signal for
solution (d) because of the absence of Ab40 aggregates. In solution
(a), there are two states for this non-conjugated FRET pair, i.e.
CRANAD-2/5 paired within the FRET distance and CRANAD-2
or -5 bound to the beta-sheets of the aggregates, though not within
the efficient FRET range. Therefore, the fluorescence intensity
(F.I.) signal at 700 nm is a sum of the FRET signal and non-FRET
signal from excitation of CRANAD-2 and CRANAD-5 at
420 nm. Since the signal from CRANAD-2 was not significant
(Fig. 2A, black line, overlapped with green line), we could
approximately estimate the respective contributions by linear
spectral unmixing using linear programming (details are described
in Text S1 and Fig. S3). The contribution of the non-FRET signal
of CRANAD-5 was about 44.8, and the actual FRET signal at
700 nm was 156.4.
We also examined the concentration ratio between CRANAD-5
and CRANAD-2, and found that once it was close to 1:1, the
intensity almost plateaued (Fig. S4). In addition, the excitation
spectra of the above solutions (a–c) were recorded by setting the
emission at 700 nm. We found two peaks for solution (a) that
corresponded to the excitation peaks of CRANAD-5 and
CRANAD-2, indicating an obvious FRET partnership between
these two molecules (Fig. 2B). When tested whether curcumin and
its analogues could form a FRET pair for the aggregates, we found
that the pair of curcumin/CRANAD-2 was able to generate a
FRET signal as well (Fig. 2C).
To test whether dimers could be used to assemble CRANAD-5/
CRANAD-2 into a FRET pair, we incubated CAPS Ab42 dimers
with the FRET partner. The Ab42 dimers were prepared as
reported [20], purified by HPLC and characterized by Western
blot. The TEM image indicated that the preparation did not
contain significant deposits (Fig. S5). Additionally, there was no
significant fluorescence intensity change with a Thioflavin T test
(data not shown). As expected, we observed the apparent FRET
Figure 1. The principle of non-conjugated small molecular FRET. Left: Mixing non-conjugated FRET partner molecules with the Ab
aggregates/fibrils, which consist of numbers of b-sheet ladders, has a high probability of incorporating the partner into the Ab species within 10 nm
proximity to generate a viable FRET signal. Right: Chemical structures of curcumin, CRANAD-2 and CRANAD-5.
doi:10.1371/journal.pone.0019362.g001
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these species could be used as an intrinsic FRET platform.
To test whether Ab monomers could be used to assist the FRET
pair in assembly, we incubated Ab40 monomers with a
CRANAD-5/-2 pair. The Ab40 monomers were prepared from
HFIP (hexafluoroisopropanol) treated solution [21], and purified
by HPLC (see Material and Methods). The monomeric state was
characterized by SDS-Page gel, and the morphology was
confirmed by TEM (Fig. S5). As we expected, no significant
FRET signal was observed at 700 nm (Fig. 3B), indicating that
these monomers do not form a FRET platform. In addition, no
significant fluorescence intensity change was observed with a
Thioflavin T test (data not shown). Similar results were obtained
with Ab42 monomers (Fig. 3A). Because the CRANAD-5/-2
FRET pair could be assembled with the assistance of HrMW
species such as dimers and aggregates, but not the monomers, we
suggested that the non-conjugated FRET technique could be used
to differentiate monomers from higher molecular weight Ab
species, such as dimers, oligomers, and aggregates.
For a given solution, we could use this method to calculate the
concentrations of monomers (C(mono)) and HrMW species
(C(hrmw)). The FRET signal at 700 nm was proportional to the
concentration of higher molecular weight species, i.e.
C hrmw ðÞ !FI FRET ðÞ ð 1Þ
Therefore, based on the FRET signal we could generate a
standard curve (Fig. 4A) described in Eq.(2),
C mono ðÞ ~0:32(C hrmw ðÞ )z4:4(r2~0:9993) ð2Þ
If the Ab species solution is a synthetic peptide solution, the total
Ab species consist of monomers and HrMW species, therefore,
(C mono ðÞ )~(C total ðÞ ){(C hrmw ðÞ ) ð3Þ
We tested a sample of 250 nM Ab40 peptide from rPeptide
(Cat. No. A-1001-2 (TFA)) by using a FRET (Fig. 4B). Using
the obtained fluorescence intensity value and the calibration
curve (Equation 2), we calculated the concentration of high
molecular weight species (C(hrmw))=102.8 nM. Next, from
Figure 2. Validation of FRET phenomenon in solution with Ab40 aggregates. (A) Spectra overlay showing FRET phenomenon in a solution
of CRANAD-5 and CRANAD-2 with Ab40 aggregates (a) (red); spectrum of control solution of CRANAD-5 with Ab40 aggregates (b) (blue); spectrum of
control solution of CRANAD-2 with Ab40 aggregates (c) (black, overlapped with the green line); spectrum of control solution of CRANAD-5 and
CRANAD-2 without Ab40 aggregates (d) (green, overlapped with the black line). (B) Excitation spectra overlay of solution (a) (red), (b) (blue) and (c)
(black) with the emission at 700 nm. Note two excitation peaks for solution (a). (C) Spectra overlay of solutions of curcumin and CRANAD-2 with Ab40
aggregates: FRET (red), spectrum of control solution of curcumin with Ab40 aggregates (blue), spectrum of control solution of CRANAD-2 with Ab40
aggregates (black), and spectrum of control solution of curcumin and CRANAD-2 without Ab40 aggregates (green).
doi:10.1371/journal.pone.0019362.g002
Figure 3. Differentiation of Ab monomers from higher molecular weight Ab species, which include aggregates/fibrils, and dimers.
(A) Spectra overlay of Ab42 dimers (red) and Ab42 monomers (black). (B) Spectra overlay of Ab40 aggregates (red) and Ab40 monomers (black).
doi:10.1371/journal.pone.0019362.g003
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(C(mono))=147.2 nM.
Due to the complicated nature of HrMW species and their
possible influence on FRET we realize that the obtained data
could only serve as the first approximation. However, we believe
that this is an important first step in identifying the amount of
various species present during AD progression.
Discussion
We demonstrated that high molecular weight Ab species could
be used as intrinsic platforms for assembling a non-conjugated
non-bioengineered FRET pair. These pairs can be used for
differentiating monomers from HrMW species, which have
neurotoxic effects. Differentiating Ab monomers from potentially
damaging species bears a potential for Alzheimer’s disease early
detection and treatment monitoring. Although the exact normal
physiological role for Ab monomers remains unknown, they have
been shown to serve as ligands for a number of different receptors
and other molecules [22]. Recently it has been indicated that Ab
monomeric peptides could be involved in the antimicrobial
function of the innate immune system [23]. Meanwhile,
aggregation of Ab monomers is probably one of the most
important initial points in AD progression. A screening method
to seek compounds capable of keeping Ab at the monomeric status
is highly desirable. We believe our approach could be used as an
inexpensive, efficient, and easy-to-use tool for monitoring the
aggregating stage from monomers to oligomers.
Currently, for biofluids with low Ab concentrations such as CSF
and cell culture medium, ELISA tests with anti-Ab antibodies are
used for quantification of concentrations of monomers, dimers, and
other HrMW species. However, this method is expensive, time-
consuming, and inconsistent within different operators and testing
centers [3,4,5,6]. For high concentration samples, CD (circular
dichroism) and QLS (quasielastic light scattering spectroscopy) have
been used tomonitortheprogression ofaggregationfrom monomers
toHrMSspecies,however,these methods are impractical forroutine
clinical sample analysis [11,24,25]. We believe our approach would
be a useful complementary tool for the above-mentioned methods.
The advantages of our method include low costs, fast reaction time,
good sensitivity, and straightforward protocol.
It is important to note that the proposed FRET platform is not
only able to differentiate monomers from HrMW species (Fig. 5 A-
1), but is also able to differentiate small oligomers from the large
size species (plaques, fibrils, profibrils and large oligomers) when it
is combined with a Thioflavin T test (Fig. 5). Thioflavin T has
been used widely to detect plaques in brain tissues and fibrils/
aggregates/profibrils in solutions [7,8,10]. It has been recently
reported that it is also capable of detecting soluble oligomers [9].
On the other hand, Biancalana et al has predicted that 4-5 beta
sheets are needed for Thioflavin T binding [7,12], indicating that
it can not detect small oligomers such as dimers and tetramers,
which have been reported as highly toxic species [26,27]. We
envision that the proposed flow chart in Fig. 5 could be used to
differentiate various Ab species. Since our FRET is able to detect
HrMW species that include large size species and small oligomers,
while Thiofalvin T is capable of detecting large size species, for a
given pure solution, if the testing results with Thioflavin T and
FRET are both positive (Fig. 5 A-2), the solution could contain
large size species. If a FRET test is positive and a Thioflavin T test
is negative (Fig. 5 A-3), the solution could contain small oligomers.
In practice, we could generate two standard curves for Thioflavin
T and FRET respectively, to estimate the concentrations of large
size species, small oligomers and monmers.
Figure 4. Testing with commercial available Ab40 peptide. (A) Standard curve of FRET with Ab40 aggregates. (B) Fluorescence spectra of Ab40
sample from rPeptide with CRANAD-5/-2 FRET pair.
doi:10.1371/journal.pone.0019362.g004
Figure 5. Flow chart and principle for differentiating various Ab
species based on non-conjugated FRET technique. (A-1)
Differentiating Ab monomers from high molecular weight species;
(A-2, A-3) differentiating large size species (A-2) from small oligomers
(A-3).
Non-Conjugated Small Molecule FRET with Ab
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concept. To achieve higher sensitivity and better selectivity, we are
currently in the process of developing a small compound library to
seek better matching pairs.
Lastly, we suggest that the proposed concept could be
generalized to other misfolding proteins/peptides such as amylin
in diabetes, prion in mad cow disease, tau protein in AD, and
a-synuclein in Parkinson disease if specific FRET matched
fluorophore pairs are found. We also envision that this technique
could be extended to studies of protein/protein and protein/RNA
interactions with fluorophore tagged ligands.
Materials and Methods
Reagents used for synthesis were purchased from Aldrich and
used without further purification. Column chromatography was
performed on silica gel slurry (SiliCycle Inc., 60 A ˚, 40-63 mm)
packed into glass columns. Synthetic amyloid-b peptide (1-40) was
purchased from rPeptide (Bogart, GA, 30622) and aggregates for
in vitro studies were generated by slow stirring for 3 days in PBS
buffer at room temperature.
1H and
13C NMR spectra were
recorded at 500 MHz and 125 MHz respectively, and reported in
ppm downfield from tetramethylsilane. Mass spectra were
obtained at Harvard University, at the Department of Chemistry
Instrumentation Facility.
Synthesis of CRANAD-2 and CRANAD-5
CRANAD-2. The synthesis was performed according to our
previously reported procedure [19].
CRANAD-5. The synthesis followed the reported procedure
with some modifications [28]. Boric oxide (700.0 mg, 10.0 mmol)
was dissolved in DMF (10.0 mL) at 120uC. Ensuring that most of
the boric oxide was dissolved was crucial for high yield. To this
solution, acetylacetone (1.1 mL, 10.0 mmol) was added, followed
by tributyl borate (5.4 mL, 20.0 mmol) at 120uC and stirred for
5 min. To the borate complex, 4-N,N’-dimethylamino-
benzaldehyde (3.1 g, 20.0 mmol) was added and stirred for
5 min. A mixture of 1,2,3,4-tetrahydroquinoline (0.2 mL) and
acetic acid (0.4 mL) in DMF (4.0 mL) was added to the reaction
mixture and heated to 120uC for 2 h. After cooling to room
temperature, the reaction mixture was poured into ice water
(500 mL), and a reddish precipitate was collected. The precipitate
was further purified with a silica gel column using ethyl acetate/
hexanes (50:50) as eluent to yield the reddish powder of
CRANAD-5 (1.8 g, 52.7 %).
1H NMR (CDCl3) d(ppm) 3.03 (s,
6H), 5.73 (s, 1H), 6.42 (d, 2H, J=16.0 Hz), 6.68 (d, 4H,
J=10.0 Hz), 7.45 (d, 4H, J=10.0 Hz), 7.60 (d, 2H, J=
16.0 Hz);
13C NMR (CDCl3) d(ppm) 40.4, 101.1, 112.1, 119.4,
123.3, 130.0, 140.8, 151.8, 183.6. The spectra were consistent
with the reported value [28].
Ab40 aggregates preparation. Ab40 peptide (1.0 mg)
powder was suspended in 1% ammonia hydroxyl solution
(1.0 mL), and 0.1 mL of the resulting solution was diluted
tenfold with PBS buffer (pH 7.4) (final concentration 25 mM)
and stirred at room temperature for 3 days. TEM was
performed using a JEOL 1011 electron microscope. Ten
microliters of the above Ab40 peptide solution was mounted
on a formava- c o a t e dc o p p e rg r i df o r5m i n u t e s ,a n dt h eg r i dw a s
dried off with filter paper. Then, 10 mlo f2 % aqueous
phosphotungstic acid (adjust pH to 7.3 using 1N NaOH) was
dropped immediately onto the grid, and left for 30 seconds. The
grid was placed directly into the grid box and allowed to air-dry
for several hours before observation. The images confirming the
formation of aggregates were taken at 80.0 kv with direct
magnification of 10,000 (Fig. S1). This solution was kept at 4uC
for storage.
Ab40/42 monomers preparation. Ab40/42 monomers
were prepared by further purification of commercially available
Ab40/42 peptide (rPeptide, catalogue No. A-1153-1 and A-1163-
1 with HFIP treatment) using HPLC. The purified monomers
were stored as powder/film. Before use, the peptides were
dissolved in hexafluoroisopropanol (HFIP) as stock solutions
[21]. SDS-gel testing of monomeric Ab40/42 peptides was
performed on a 4–20% gradient Tris gel (Bio-Rad) and
SeeBlueHplus2 (Invitrogen)(4–250 KD) was used as a molecular
weight marker. A ten microliter sample (25 mM) was loaded and
MES buffer was used for running the gel. Both SDS-GEL and
TEM results confirmed that the products were not oligomerized or
aggregated (data shown in Fig. S5).
Ab42 dimers preparation. Ab42 dimers were prepared by
following the reported procedure [20] (the detailed procedure is
described in Text S1). Western blot for CAPS Ab42 dimers and
Ab42 monomers was performed using monoclonal antibody mAb
6E10 raised against residues 1–17 of the Ab peptide (Calbiochem)
(data shown in Fig. S5).
Binding constant measurements. To PBS solutions
(1.0 mL) of Ab40 aggregates (2.5 mM, calculation based on
Ab40 peptide concentration), various amounts of CRANAD-5
were added to final concentrations of 5.0, 10.0, 20.0, 40.0, 100.0,
200.0 nM, and their fluorescence intensities at 610 nm were
recorded (Ex: 520 nm). The Kd binding curve was generated
using Prism 5.0 software with nonlinear one-site binding regression
to give Kd=10.562.5 nM.
Spectral overlap measurements. Emission spectra were
recorded for a solution of curcumin (0.5 mM) and Ab40 aggregates
(1.0 mM) in PBS (1.0 mL) (Ex: 470 nm, Ex slit=10 nm, and Em
slit=10 nm), and normalized to the highest reading of 1.0. For the
excitation spectrum of CRANAD-2, a solution of CRANAD-2
(0.5 mM) and Ab40 aggregates (1.0 mM) in PBS (1.0 mL) were
used (Em: 800 nm, Ex slit=10 nm, and Em slit=10 nm). The
recorded spectrum was normalized to the highest reading of 1.0.
The final spectral overlap was generated using Prism 5.0 software.
FRET. A solution of Ab40 aggregates (1.0 mM) was mixed
with 0.5 mM of CRANAD-2, and incubated at room temperature
for 1 min, following by the addition of 0.5 mM of CRANAD-5 (a).
The FRET spectrum of the resulted solution was measured within
1 min (Ex: 420 nm, Ex slit=10 nm, and Em slit=10 nm). As
controls, a solution of 0.5 mM CRANAD-5 with Ab40 aggregates
(1.0 mM) (b), a solution of 0.5 mM CRANAD-2 with Ab40
aggregates (1.0 mM) (c) and a solution of 0.5 mM CRANAD-5
and 0.5 mM CRANAD-2 without aggregates (d) were used.
A similar procedure was used for recording the FRET spectrum
of the curcumin/CRANAD-2 pair (Ex: 470 nm, Ex slit=10 nm,
and Em slit=10 nm). For excitation spectra recording, Em=
700 nm was used, with 10 nm Em/Ex slits.
Standard curve of FRET. Fluorescence spectra of
CRANAD-5/-2 FRET pair (250 nM for both compounds) with
50, 100, 150, 250 nM Ab40 aggregates were recorded. The
standard curve was plotted as Ab40 aggregates concentration vs.
FI at 700 nm, and fitted using linear regression.
Supporting Information
Figure S1 TEM image of the Ab40 aggregates.
(PNG)
Figure S2 Upper: Excitation and emission spectra of CRA-
NAD-5 (with Abeta40 aggregates); Middle: Excitation and
emission spectra of CRANAD-2 (with Abeta40 aggregates); and
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excitation of CRNAD-2.
(PNG)
Figure S3 Approximate estimation of the actual FRET signal by
linear spectral unmixing. Red line is the measured FRET
spectrum; green line is the unmixed spectrum for CRANAD-5
with Ab40 aggregates; blue line is the unmixed spectrum for actual
FRET spectrum without contamination from the non-FRET
signal of CRANAD-5.
(PNG)
Figure S4 The titration curve of CRANAD-2 (250 nM) with
various concentrations of CRANAD-5.
(PNG)
Figure S5 (A) SDS-Page gel of Abeta40 and Abeta42 mono-
mers; (B) TEM image of Abeta40 monomers (negative staining
with PTA); (C) Western-blot of Abeta42 dimers; (D) TEM image
of Abeta42 dimers. Scale bar: 100 nm.
(PNG)
Text S1 Brief description of Preparation of dimeric Ab fractions
and Spectral unmixing method.
(DOC)
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